Banner Alzheimer’s Institute (BAI) has received a grant expected to total $27.5 million over five years from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to further investigate biological and cognitive changes preceding the onset of memory and thinking problems in people at different levels of genetic risk for Alzheimer’s disease. Led by researchers from Banner and Mayo Clinic in Arizona, the five-year grant will study healthy people with six forms of the apolipoprotein E (APOE) gene, the major genetic risk factor for Alzheimer’s disease, create a shared scientific resource of data and biological samples to support a wide range of future studies, and help to advance the understanding, treatment, and prevention of Alzheimer’s disease.Continue reading
Category Archives: AZBio News
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma
In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses1
Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are mostly low-grade with early onset and resolution1
BD to Invest $65 Million for Key Supply Chain Infrastructure in Tucson, Arizona to Increase Resiliency of U.S. Medical Device Supply
NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins
Early-stage trial to evaluate safety and immunogenicity.
In investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate’s safety and immunogenicity in adult volunteers. The vaccine, known as mRNA-1273.351, was developed by the biotechnology company ModernaTX, Inc., based in Cambridge, Massachusetts. The trial is led and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial will enroll approximately 210 healthy adult volunteers at four clinical research sites in the United States that are part of the NIAID-funded Infectious Diseases Clinical Research Consortium(IDCRC).
BD Announces FDA Emergency Use Authorization for Combination COVID-19, Flu Rapid Antigen Test
FRANKLIN LAKES, N.J., March 30, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for a new, rapid antigen test that can detect SARS-CoV-2, influenza A and influenza B in a single test.
Mayo Clinic and ASU MedTech Accelerator boosts health startups
The partnership propels a new cohort of next-generation medical technology and service startups forward with one-of-a-kind tools and resources.
Few things have better illustrated the need for innovative medical technologies than the COVID-19 pandemic. The Mayo Clinic and ASU MedTech Accelerator, a flagship program of the Mayo Clinic and ASU Alliance for Health Care, was designed to help empower medical startups to better navigate challenges while bringing forth life-changing health innovations. The second cohort of this program is set to launch March 30, 2021.
Life365 Adds AliveCor’s Personal EKG Technology to their Virtual Care Platform
SCOTTSDALE, AZ, March 30, 2021— Life365, a leading virtual care platform provider, announced its integration of products from AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, to enhance their remote cardiac monitoring solutions for healthcare consumers and patients located outside traditional care settings.
850 PBC Opens on the Phoenix Biomedical Campus
Located adjacent to ASU’s downtown campus, the Phoenix Biomedical Campus (PBC) Innovation Center expands the downtown biomedical corridor to the northern edges of the urban core. Designed to integrate research, entrepreneurial activity, and corporate engagement, the building offers opportunities for meaningful collaboration with the building tenants and community.Continue reading
Equine Amnio Solutions Signs Exclusive Agreement For Distribution Of RenoVō®, A Next-Generation Equine Regenerative Product
ARGYLE, Texas, March 25, 2021 /PRNewswire/ — Equine Amnio Solutions, LLC (EAS), a distributor of advanced, next-generation equine regenerative products, announced today that Covetrus, a global leader in animal-health technology and services, will be the exclusive distributor of the RenoVō® equine allograft throughout the United States.
UArizona Health Sciences, Cancer Center Launching Arizona Clinical Trials Network
Arizona residents, including underserved and underrepresented populations, will have better access to cutting-edge cancer therapies as the UArizona Cancer Center offers its clinical trials at locations across the state.Continue reading